Cargando…
Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies
Treatment with rituximab, a monoclonal antibody against the B-lymphocyte surface protein CD20, leads to the depletion of B cells. Recently, rituximab was reported to effectively prevent relapses of glucocorticoid-dependent or frequently relapsing minimal change disease (MCD). MCD is thought to be T-...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433659/ https://www.ncbi.nlm.nih.gov/pubmed/28540057 http://dx.doi.org/10.1177/2054358117698667 |